| Background and objective Worldwide, lung cancer is the most common malignancy in terms of incidence and mortality. In recent years, anti-angiogenesis drugs have been used more and more frequently in cancer treatment. This study was performed to evaluate the efficacy and toxicity of recombinant human endostatin (trade name: Endostar) combined with platinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC).Methods Thirty two advanced NSCLC patients received Endostar combined with platinum-based chemotherapy for more than two cycles. The patients were given standard follow-up treatment according to National Comprehensive Cancer Network guidelines after disease progressed. The evaluation parameters included overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and adverse reactions.Results Of the32patients assessable for radiological response,9achieved partial response,16had stable disease,7had progressive disease, and no one achieved complete response. The ORR was28.1%, and DCR was78.1%. The median PFS was6.0months (95%confidence interval [CI]:4.4-7.6months). The median OS was22.0 months (95%CI:16.7-27.3months). There were no significant differences in ORR, DCR and PFS between the patients who had different pathological features, those had naive or relapsed diseases, those were administered endostatin through intravenous drip or continuous pumping, or those received different chemotherapeutic regimens (P>0.05). The total incidence rates of leucopenia, decreased hemoglobin and thrombocytopenia were65.6%,75%and40.6%, respectively. The frequencies of grade Ⅲ～Ⅳ leucopenia, decreased hemoglobin and thrombocytopenia were31.2%,12.5%and6.3%, respectively. One had grade Ⅲ hypertension; two had arrhythmia; one had grade Ⅲ hepatic dysfunction.Conclusions Endostar combined with platinum-based chemotherapy had good short-term efficacy and was well-tolerable for advanced NSCLC patients. |
PDF Full Text Request